Memory loss is a major complaint among the elderly population. Claimed to enhance cognitive function and readily accessible in pharmacies and food stores, phospholipids supplementation has produced mixed findings in several studies. A group of healthy adults and elderly volunteers (n=522) aged 65,84±10,74 years with an education level of 7,90±4,90 years participated in the study. Participants were submitted to the Mini-Mental State Examination (MMSE), Scale Memory Complaints (SMC) and Geriatric Depression Scale (GDS). Three individuals presented cognitive impairment, 505 presented memory complaints and 257 were above cut-off point for GDS. Subsequently, one female group (n=17) used phospholipids supplementation for 4 weeks. After the period of supplementation, a decrease in mean SMC and GDS values were observed. Phospholipids consumption over the course of 4 weeks significantly decreased SMC (p<0,05) values in this female group. Biomedical and Biopharmaceutical Research J o r n a l d e I n v e s t i g a ç ã o B i o m é d i c a e B i o f a r m a c ê u t i c a Biomed Biopharm Res. , 2012; (9) 2: 141-146

Biomedical and Biopharmaceutical Research J o r n a l d e I n v e s t i g a ç ã o B i o m é d i c a e B i o f a r m a c ê u t i c a AbstractThis study aims to evaluate the effect of phosphatidylserine supplementation on Scale Memory Complaints (SMC) and Geriatric Depression Scale (GDS). A group of healthy adults and elderly people (n= 915) aged 65,65 ± 11,10 years with an education level of 7,56 ± 4,56 years participated in the study. Participants were submitted to the Mini-Mental State Examination (MMSE), SMC and GDS. Four individuals presented cognitive impairment, 874 presented memory complaints and 436 were above cut-off point for GDS. Subsequently, one group of women (n=48) used phosphatidylserine supplementation for 4 weeks. The consumption of phosphatidylserine over the course of 4 weeks significantly decreased SMC (p=0,000) and GDS (p=0.009) values in this group.